Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334617 · ClinicalTrials.gov registry record · Phase 2
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 528
- Enrollment target
- 20
- Study locations
NCT03334617 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 528 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03334617, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 528 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Durvalumab
- DRUG Ceralasertib
- DRUG Danvatirsen
- DRUG Vistusertib
Study Locations (20)
California
- Research Site - Duarte
- Research Site - Fullerton
- Research Site - La Jolla
- Research Site - Los Angeles
Other
- Research Site - Innsbruck
- Research Site - Salzburg
- Research Site - Vienna
Maryland
- Research Site - Baltimore
- Research Site - Baltimore
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
Tennessee
- Research Site - Nashville
- Research Site - Nashville
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2026-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03334617
The ClinicalTrials.gov registry entry for NCT03334617 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (20% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Olaparib is the first listed.
NCT03334617 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Other, Maryland.
Frequently Asked Questions
What is clinical trial NCT03334617 about?
NCT03334617 is a clinical study titled "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy". This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
What is the current status of trial NCT03334617?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 528 participants. The study started on 2017-12-18. Estimated completion is 2026-09-11.
What conditions does trial NCT03334617 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03334617?
The interventions under investigation include: Olaparib (DRUG), Durvalumab (DRUG), Ceralasertib (DRUG), Danvatirsen (DRUG), Vistusertib (DRUG).
Who is sponsoring clinical trial NCT03334617?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03334617 being conducted?
This trial has 20 study locations across California, District of Columbia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.